홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Doxorubicin Hydrochloride → Doxorubicin

HRID 1034376
인쇄

반응식

HRID 1034376 반응식
[CH3:1][C@@H:2]1[O:7][C@@H:6]([O:8][C@@H:9]2[C:14]3=[C:15]([OH:32])[C:16]4[C:28](=[O:29])[C:27]5[C:22](=[CH:23][CH:24]=[CH:25][C:26]=5[O:30][CH3:31])[C:20](=[O:21])[C:17]=4[C:18]([OH:19])=[C:13]3[CH2:12][C@@:11]([OH:37])([C:33]([CH2:35][OH:36])=[O:34])[CH2:10]2)[CH2:5][C@H:4]([NH2:38])[C@@H:3]1[OH:39].Cl>CC(N(O)CCCCCNC(CCC(N(O)CCCCCNC(CCC(N(O)CCCCCN)=O)=O)=O)=O)=O.CS(O)(=O)=O>[CH3:1][C@@H:2]1[O:7][C@@H:6]([O:8][C@@H:9]2[C:14]3=[C:15]([OH:32])[C:16]4[C:28](=[O:29])[C:27]5[C:22](=[CH:23][CH:24]=[CH:25][C:26]=5[O:30][CH3:31])[C:20](=[O:21])[C:17]=4[C:18]([OH:19])=[C:13]3[CH2:12][C@@:11]([OH:37])([C:33]([CH2:35][OH:36])=[O:34])[CH2:10]2)[CH2:5][C@H:4]([NH2:38])[C@@H:3]1[OH:39]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

3

반응물 1

HCID 443939Doxorubicin Hydrochloride

생성물 1

HCID 31703Doxorubicin

시약·촉매·용매 1

HCID 62881Deferoxamine Mesylate용매

실험 절차

1 ml of a 10 mg/ml solution of doxorubicin HCl dissolved in saline-desferal was added to I ml of the liposome dispersion after the liposomes were gel filtrated on a Sephadex G-50 column in Step B. The mixture was incubated at room temperature for approximately 24 hours. The incubation was shorter for certain types of kinetic experiments. At the end of incubation period, the mixture was passed through a Dowex 50 WX-4 (Serva) column to adsorb the free, unincorporated drug. As small amount as 60 mg of the resin was able to adsorb as much as 1 mg of free doxorubicin in a time shorter than less than 15 minutes. Liposome incorporated doxorubicin did not adsorb to the Dowex resin at all and remained in the liposomes. A column containing 1-2 g dry weight of the resin was sufficient to adsorb all unincorporated drug. To determine the ratio of incorporated drug to liposomal lipid, the phospholipids and doxorubicin concentration were determined. PC concentration was determined according to Anal. Biochem., 104: 10-14 (1980) modified so that 20 ul of 10M HCl were added to the assay mixture, in order to avoid partitioning of doxorubicin into the organic phase of the assay. EPC was used for a standard curve.

후처리

  1. additionwas added to I ml of the liposome dispersion after the liposomes
  2. filtrationfiltrated on a Sephadex G-50 column in Step B
  3. customshorter than less than 15 minutes
  4. additionA column containing 1-2 g
  5. customdry weight of the resin
  6. concentrationthe phospholipids and doxorubicin concentration
  7. concentrationPC concentration
  8. additionwere added to the assay mixture, in order
  9. customto avoid partitioning of doxorubicin into the organic phase of the assay

출처 및 근거

ORD 기록
ord-22a909f929d04bfdb2fdd60c69a4b56b
출처 데이터셋
uspto-grants-1994_05
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US05316771

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트